

Not for release to US wire services or distribution in the United States

2 January 2024

Dear Eligible Shareholder,

Entitlement Offer - Additional payment option for New Zealand shareholders

As set out in its announcement on Thursday, 21 December 2023, Genetic Signatures Limited ACN 095 913 205 (**Genetic Signatures** or the **Company**) is undertaking a non-renounceable entitlement offer, whereby Eligible Shareholders will be offered the opportunity to acquire 1 new fully paid ordinary share in Genetic Signatures (**New Share**) for every 6.65 fully paid ordinary shares in Genetic Signatures held as at the Record Date (being 7:00pm on Thursday, 28 December 2023) at an issue price of \$0.37 per New Share, with no minimum subscription (**Offer**). Capitalised terms used but not defined in this letter have the same meaning ascribed to those terms in the Offer Booklet dated 2 January 2024 issued by the Company in respect of the Offer (**Offer Booklet**).

To facilitate payment of Application Monies from Eligible Shareholders located in New Zealand (**New Zealand Shareholders**), in addition to the option of making payment via BPAY®, Genetic Signatures is pleased to offer its New Zealand Shareholders the opportunity to remit their Application Monies by international electronic funds transfer (**EFT**) to the following Australian bank account:

Bank:	St George Bank
Address:	IBN 82, 1 King Street, Concord West NSW 2138
BSB:	332-027
Account Number:	
Account Name:	Boardroom Pty Limited ITF Genetic Signatures Limited
Swift Code:	SGBLAU2S

Please note that the Application Monies remitted by you will be subject to international transfer and foreign currency conversion fees levied by your financial institution such that the amount received by Genetic Signatures in Australian dollars will be less than the amount remitted by you in New Zealand dollars.

If you wish to take up all or part of your Entitlement (on the terms set out in the Offer Booklet), you will need to ensure that the amount paid by you takes into account any international transfer and foreign currency conversion fees levied by your financial institution.

In this case, you will need to confirm this amount with your financial institution prior to paying your Application Monies to Genetic Signatures and pay an additional amount to cover these fees as Genetic Signatures will only issue New Shares based on the actual amount of Application Monies that it receives.

If your Application Monies do not pay for your full Entitlement, you are deemed to have only taken up your Entitlement in respect of such whole number of New Shares that is covered in full by your Application Monies.

For processing and reconciliation, when making your payment, please add to the remittance advice your CRN which appears under the Biller Code on the front of your personalised Entitlement and Acceptance Form and forward a copy of the remittance advice and entitlement form to Genetic Signatures' Share Registry, Boardroom Pty Limited, by e-mail to corporateactions@boardroomlimited.com.au, as soon as the payment is made. Failure to do so may result in

funds not being matched to your application and Genetic Signatures being unable to issue you New Shares under the Offer.

Eligible Shareholders are reminded that the Offer is expected to close at 5:00pm (Sydney, Australia time) on Thursday, 18 January 2024 (Closing Date) and any payment received after the Closing Date may be rejected.

If you are interested in applying for New Shares under the Offer, you are advised to arrange for payment of Application Monies as early as possible and to allow sufficient time for the Application Monies to be transferred and received by Genetic Signatures by the Closing Date.

If you have any additional questions regarding the Offer, please contact the Share Registry on +61 2 9290 9600 from 9:00am to 5:00pm (Sydney, Australia time) Monday to Friday (excluding public holidays) or by e-mail to corporateactions@boardroomlimited.com.au.

Yours faithfully,

A handwritten signature in blue ink, appearing to read 'Karl Pechmann', is positioned above the printed name and title.

**Karl Pechmann
Company Secretary
Genetic Signatures Limited**